Related Experiment Video
Updated: Jul 14, 2026
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Successful Treatment of Severe and Refractory Eosinophilic Pustular Folliculitis with Dupilumab: A Case Report with
Xiaoyun Jiang1, Xia Wu1, Siji Chen1
1Department of Dermatology and Venereology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
Background:
Eosinophilic pustular folliculitis (EPF) is a rare chronic inflammatory skin disease characterized by eosinophilic infiltration and recurrent sterile pustules. Current treatments are often ineffective, and the disease frequently relapses.
Methods:
We report a case of a 71-year-old female with severe EPF and a 17-year history of recurrent pruritic papulopustular eruptions. Dupilumab was administered subcutaneously with a 600 mg loading dose followed by 300 mg every two weeks over two treatment courses, separated by a five-month loss to follow-up.
Results:
After dupilumab therapy, the patient's skin lesions completely resolved, accompanied by a marked decrease in peripheral eosinophil counts. During a 2-year follow-up, no recurrence was observed.
Conclusion:
Dupilumab demonstrated significant efficacy and safety in this severe and refractory EPF case, resulting in long-term remission without relapse, and highlighting its potential as a novel treatment option for EPF.
